Endocrine Abstracts

Introduction: Today simultaneous pancreas-kidney transplantation (SPKT) is an effective method of treatment for patients with type 1 diabetes mellitus (T1D) and terminal stage of diabetic nephropathy (DN) on renal replacement therapy by hemodialysis. It solves several problems: reduces the severity of intoxication syndrome, contributes to the achievement of euglycemia in most cases, that allows to delay progression of micro- and macrovascular diabetic complications. Case Descr...

Background and aims: Hyperglycemia can be a risk factor for adverse cardiovascular and cerebrovascular events. However, changes in platelets and coagulation hemostasis during hyperglycemia have not been extensively studied. The aim of this study was to assess the impact of level of fasting plasma glucose, HbA1c on the platelet activity, the physiological anticoagulant activity and fibrinolysis in patients with Diabetes Mellitus type 1 (DM1).Ma...

Background and aims: In 2005, experts from the IDF assigned the risk of developing coronary heart disease in patients with type 1 diabetes mellitus (DM1) at age of 30 and over or patients with DM1 with kidney damage equal to the patients with type 2 diabetes mellitus. The need for a non-invasive preclinical marker for identifying patients with the increased risk of cardiovascular disease is obvious. The assessment of arterial stiffness can play a role of such marker. The aim o...

Background and aims: To evaluate the level of tubular and glomerular biomarkers of kidney injury as potential nephroprorotective effects of GLP-1R agonist (liraglutide) addition in type 1 diabetic patients compared to standard insulin therapy.Materials and methods: 12 T1DM patients with normo-(AER <20 mg/l, n=7) and microalbuminuria (AER<199 mg/l, n=5) with liraglutide 1.2 mg as add on to insulin for 6 month and 12 patients with...

Background and aims: Microalbuminuria (MA) is not specific predictor of early stages of chronic kidney disease (CKD) in diabetes. We investigate several markers that might be useful in assessing early kidney damage in T1DM and T2DM patients additional to MA.Materials and methods: We examined 111 patients (T1DM/T2DM: 51/60) with AER<20 mg/l (n=80); <199 mg/l (n=18); ≥200 mg/l (n=13). Biomarkers of kidney damage (c...

Aim: To assess the association of the endothelial dysfunction (ED) parameters and the lipid-lowering response to atorvastatin therapy in patients with T2D with genetic markers of inflammation.Methods: We include 97 T2D patients with first prescribed atorvastatin 10–20 mg: M/F 26/71; mean age 57 years. After 12 month of statin therapy, patients had fasting lipid profiles and ED parameters repeated. For ED evaluation, we performed pulse wave analysis ...

Aim: To evaluate the effect of PPARG2 Pro12Ala, TNFα G(308)A and G(238)A, LIPC C(-514)T, ACE I/D, SLCO1B1 Val174Ala polymorphism on the response to statins therapy in patients with type 2 diabetes mellitus (T2DM).Methods: We consecutively recruited patients with type 2 DM requiring lipid-lowering therapy according to current guidelines. Patients were started on either atorvastatin 10 or 20 mg. After 12 month of st...

Objective: To evaluate the impact of different modes of insulin therapy (continuous subcutaneous insulin infusion (CSII) using insulin pump or multiple insulin injections (MII)) on carbohydrate metabolism, the state of the transplant, cardiovascular system, calcium and phosphorus metabolism in patients with type 1 diabetes (DM1) during the 1st year after kidney transplantation (KT).Materials and methods: The study included patients with DM1 after transpl...

Background and aims: Cerebrovascular reactivity (CVR) impairment was reported as a marker of cerebral microangiopathy in long-term type 1 diabetes (DM1). Indices of cerebral blood flow might serve as an indicator of early microangiopathic complications. The aim of this study was to evaluate CVR in patients with DM1 and diabetic nephropathy. Research design and methods: Study has been reviewed by the Local Ethics Committee. The study has been performed in accordance with ethica...

BackgroundThe kidney or kidney-pancreas transplantation corrects many of the metabolic or biochemical abnormalities associated with chronic kidney disease (CKD); however, mineral bone disease (MBD) and cardiovascular pathology remain frequent in transplant recipients. This happens especially in patients who have long history of secondary hyperparathyroidism (SHPT), as well immunosuppressive therapy plays an important role in the progression of MBD.<p...